QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (15) Citing Articles via Google Scholar Google Scholar Articles by Osoba, D. Articles by Yung, W.K. A. Search for Related Content PubMed PubMed Citation

Effect of disease burden on health-related quality of life in patients with malignant gliomas

Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada (D.O.); Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey, UK (M.B.); M787 Department of Neurosurgery, University of California, San Francisco, CA 94143 (M.D.P.); Department of Neuro-Oncology, M.D. Anderson Cancer Center, Houston, TX 77030 (W.K.A.Y.)

² Address correspondence and reprint requests to David Osoba, QOL Consulting, 4939 Edendale Ct., West Vancouver, BC, Canada V7W 3H7.

Abstract

The burden imposed by disease recurrence in patients with high-grade gliomas is not well documented. We studied the frequency of self-report symptoms and the effects on health-related quality of life in patients who had recurrent glioblastoma multiforme or anaplastic astrocytoma and who had a Karnofsky performance score 70. Patients completed the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 Items (QLQ-C30) and the Brain Cancer Module (BCM20) before initiation of treatment for first recurrence of disease. Six symptoms (fatigue, uncertainty about the future, motor difficulties, drowsiness, communication difficulties, and headache) were reported with a frequency >50% by both groups of patients. An additional two symptoms (visual problems and pain) were also reported with frequencies of >50% by patients with recurrent glioblastoma multiforme. Most of the symptoms were likely due to recurrence, but previous radiation therapy and on-going corticosteroid treatment may have also been casual factors for fatigue, whereas uncertainty about the future and pain were probably nonspecific for brain cancer. Problems with motor functioning, vision, leg strength, and pain were reported more frequently by patients with recurrent glioblastoma multiforme than by those with recurrent anaplastic astrocytoma. Scores on health-related quality-of-life functioning scales were similar in the two groups. Finally, the scores for patients who had recurrent high-grade gliomas and a Karnofsky performance score 70 were compared with the reported health-related quality of life scores of patients with other cancers. Their scores were similar to those of patients with metastatic cancers and worse than those of patients with localized cancers.

This article has been cited by other articles:

				S. Faithfull, K. Cook, and C. Lucas Palliative care of patients with a primary malignant brain tumour: case review of service use and support provided Palliative Medicine, October 1, 2005; 19(7): 545 - 550. [Abstract] [PDF]

				A R Giovagnoli, A Silvani, E Colombo, and A Boiardi Facets and determinants of quality of life in patients with recurrent high grade glioma J. Neurol. Neurosurg. Psychiatry, April 1, 2005; 76(4): 562 - 568. [Abstract] [Full Text] [PDF]